Creutzfeldt-Jakob disease - Treatment with human pituitary growth hormone Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16283]
16373 there is some evidence that treatment with human pituitary growth hormone may be a factor in the development of the condition under consideration.
16287 the veteran has had treatment with human pituitary growth hormone at some time.
the veteran had treatment with human pituitary growth hormone before the clinical onset of Creutzfeldt-Jakob disease.16289 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and VEA service for Creutzfeldt-Jakob disease.
16292 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and operational service for the clinical onset of Creutzfeldt-Jakob disease.
or
16293 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and eligible service for the clinical onset of Creutzfeldt-Jakob disease.
Clinical onset and operational service [16292]
the veteran had treatment with human pituitary growth hormone before the clinical onset of Creutzfeldt-Jakob disease, on operational service.or
the treatment with human pituitary growth hormone before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.16295 — the identified illness or injury for which treatment with human pituitary growth hormone was given is causally related to operational service.
Clinical onset and eligible service [16293]
the treatment with human pituitary growth hormone before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.16296 — the identified illness or injury for which treatment with human pituitary growth hormone was given is causally related to eligible service.